Postmarketing observation shows increased risk for Guillain-Barré syndrome for 42 days postvaccination
MONDAY, Jan. 13, 2025 (HealthDay News) — The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial virus (RSV) vaccines to include warnings and precautions about the risk for Guillain-Barré syndrome (GBS).
For each vaccine, postmarketing observational studies suggest an increased risk of GBS during the 42 days following vaccination.
Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk. Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, as well as individuals aged 18 to 59 years at increased risk. Abrysvo is also approved for pregnant individuals at 32 through 36 weeks of gestational age for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age.
Rapid Practice Points Developed for RSV Vaccines in Adults 
Reduced Risk for Invasive Cervical Cancer Persists After HPV Vaccination 
Birth Dose of Hepatitis B Vaccination Safe, Effective 
Substantial Number of Older Adults Do Not Think They Need Flu, COVID-19 Vaccines 
2011 to 2023 Saw Rise in Discharges to Hospice After ICU Admission 
Male Sex, Older Age Predict Poor Outcomes in Seniors With HFmrEF/HFpEF 
Exposure to Low-Credibility Health Content Limited but Increases With Age 
Short-Term Surgical Outcomes at Rural Facilities Similar to Those in More Distant, Urban Facilities 
